Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system

References

• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149.
   PubMed Web of Science ®Google Scholar
• Shiff NJ, Oen K, Kroeker K, et al. Trends in population-based incidence and prevalence of juvenile idiopathic arthritis in Manitoba, Canada. Arthritis Care Res (Hoboken). 2019;71(3):413–418.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778.
   PubMed Web of Science ®Google Scholar
• Barth S, Haas JP, Schlichtiger J, et al. Long-term health-related quality of life in german patients with juvenile idiopathic arthritis in comparison to German general population. PLoS One. 2016;11(4):e0153267.
   PubMed Web of Science ®Google Scholar
• Tollisen A, Selvaag AM, Aulie HA, et al. Physical functioning, pain and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year follow-up study. Arthritis Care Res (Hoboken). 2017.
   Web of Science ®Google Scholar
• Muller-Godeffroy E, Lehmann H, Kuster RM, et al. [Quality of life and psychosocial adaptation in children and adolescents with juvenile idiopathic arthritis and reactive arthritis]. Z Rheumatol. 2005;64(3):177–187.
   PubMed Web of Science ®Google Scholar
• Albers HM, Wessels JA, van der Straaten RJ, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheumatism. 2009;61(1):46–51.
   PubMed Web of Science ®Google Scholar
• Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2006;20(2):279–300.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294(13):1671–1684.
   PubMed Web of Science ®Google Scholar
• Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109(1):109–115.
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Listing J, et al. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27(5):863–869.
   PubMed Web of Science ®Google Scholar
• Haapasaari J, Kautiainen HJ, Isomaki HA, et al. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286–2289.
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Duffy C, Malleson P, et al. Economic impact of juvenile idiopathic arthritis. Arthritis Rheumatism. 2007;57(1):44–48.
   PubMedGoogle Scholar
• Zorginstituut Nederland. Farmacotherapeutisch Kompas. 2019.
   Google Scholar
• Bouaddi I, Rostom S, El Badri D, et al. Impact of juvenile idiopathic arthritis on schooling. BMC Pediatr. 2013;13:2.
   PubMed Web of Science ®Google Scholar
• Kuhlmann A, Schmidt T, Treskova M, et al. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17(Suppl 1):79–87.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatr Clin North Am. 2018;65(4):691–709.
   PubMed Web of Science ®Google Scholar
• Davies R, Gaynor D, Hyrich KL, et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review. Semin Arthritis Rheum. 2017;46(5):584–593.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, Nigrovic PA. Editorial: toward personalized treatment for systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(8):1172–1174.
   PubMed Web of Science ®Google Scholar
• Funk RS, Becker ML. Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy. Expert Rev Precis Med Drug Dev. 2016;1(1):53–68.
   Web of Science ®Google Scholar
• Huang B, Qiu T, Chen C, et al. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 2020;6(1):e001091.
   Web of Science ®Google Scholar
• Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969–974.
   PubMed Web of Science ®Google Scholar
• Klein-Wieringa IR, Brinkman DMC, Ten Cate R, et al. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? Curr Opin Rheumatol. 2020;32(5):403–413.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–828.
   PubMed Web of Science ®Google Scholar
• Kip MMA, Currie G, Marshall DA, et al. Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Pediatr Rheumatol Online J. 2019;17(1):20.
   PubMedGoogle Scholar
• Swart JF, van Dijkhuizen EHP, Wulffraat NM, et al. Clinical juvenile arthritis disease activity score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Ann Rheum Dis. 2018;77(3):336–342.
   PubMed Web of Science ®Google Scholar
• Conti G, Chirico V, Porcaro F, et al. Frequency and identification of risk factors of uveitis in juvenile idiopathic arthritis: a long-term follow-up study in a cohort of Italian children. J Clin Rheumatol. 2019. DOI:https://doi.org/10.1097/RHU.0000000000001104.
   Web of Science ®Google Scholar
• Pedersen TL. ggforce: accelerating ‘ggplot2ʹ. R package version 0.3.1. 2019.
   Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.
   Google Scholar
• Wickham H, François R, Henry L, et al. A grammar of data manipulation. R package version 0.8.3. 2019.
   Google Scholar
• Wickham H. ggplot2: elegant graphics for data analysis. New-York: Springer-Verlag; 2016.
   Google Scholar
• Grolemund G, Wickham H. Dates and times made easy with lubridate. J Stat Softw. 2011;40(3):1–25.
   Web of Science ®Google Scholar
• Lemon J. Plotrix: a package in the red light district of R. R-News. 2006;6(4):8–12.
   Google Scholar
• Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019;71(7):1163–1173.
   PubMed Web of Science ®Google Scholar
• Allaire SH, DeNardo BS, Szer IS, et al. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952–955.
   PubMed Web of Science ®Google Scholar
• Angelis A, Kanavos P, Lopez-Bastida J, et al. Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom. BMC Musculoskelet Disord. 2016;17:321.
   PubMed Web of Science ®Google Scholar
• Ens A, Lang B, Ramsey S, et al. The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatr Rheumatol Online J. 2013;11(1):24.
   PubMedGoogle Scholar
• Epps H, Ginnelly L, Utley M, et al. Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess. 2005;9(39):iii–iv, ix–x, 1–59.
   PubMed Web of Science ®Google Scholar
• Luca NJ, Burnett HF, Ungar WJ, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1803–1811. .
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cooper K, Harris P, et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222.
   Google Scholar
• Minden K, Niewerth M, Listing J, et al. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(7):836–842.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034–1043. .
   PubMed Web of Science ®Google Scholar
• Barber CEH, Barnabe C, Benseler S, et al. Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2020;18(1):22. .
   PubMed Web of Science ®Google Scholar